miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 5, 2026

Central Garden & Pet reaffirms $2.70+ EPS target for 2026 while shifting focus to innovation and growth

View original at seekingalpha.com
Central Garden & Pet reaffirms $2.70+ EPS target for 2026 while shifting focus to innovation and growth Earnings Call Insights: Central Garden & Pet Company (CENT) Q1 2026 MANAGEMENT VIEW * CEO Nicholas Lahanas opened the call highlighting "improved gross margins and solid earnings per share, especially when compared t…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • It's time to pivot and focus on a growth mindset, including picking up private label, M&A, driving market share in categories, and investing in digital

    80% confidence

  • Central Garden & Pet expects fiscal 2026 non-GAAP diluted EPS of $2.70 or better

    80% confidence

  • Improved gross margins and solid earnings per share, especially when compared to a strong prior year first quarter that benefited from favorable shipment timing, promotional activity and weather

    80% confidence

  • Pet adoption has definitely hit the bottom and is tilted towards coming back up, with stabilization and positive growth in live animal business

    80% confidence

  • Inventories and barns are in great shape and the company is ready to be pressure tested if spring weather is favorable

    80% confidence

  • The total distribution points of products that Central Garden manufactures is up 14% year-over-year, showing optimism for growth and continued retailer support

    80% confidence

  • Shipment timing was more than half of the overall net sales decline, with portfolio optimization accounting for almost the rest

    80% confidence

  • The discipline around managing costs and operational simplicity is now firmly embedded in the company's culture

    80% confidence

  • The company is applying the same clarity, focus and consistency to fostering a growth mindset and embedding innovation more deeply across the organization

    80% confidence

  • Net sales were $617 million, a 6% year-over-year decline with 2 primary factors that accounted for substantially all of the change: timing of retailer spring inventory shipments and continued portfolio optimization efforts

    80% confidence

  • Over the past several years, the company focused on simplifying the business, improving efficiency and maintaining profitability across both segments, and that work continues to show up in results

    80% confidence

  • Durables were about 16% of Pet segment sales in Q1, consistent with Q4, with decline north of 20%

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Central Garden & Pet reaffirms $2.70+ EPS target for 2026 while shifting focus to innovation and growth — Source | Via News | es.VIA.NEWS